Today I am pleased to announce our strong 2024 financial results. We had another year of growth and made significant strategic progress across the Group. I'm proud to say that for the first time we generated over 3 billion dollars of annual revenue, and we expect growth to continue into 2025. Importantly each of our three divisions contributed to our top-line growth, demonstrating the strength of our business.

Injectables, our largest business, grew across all regions. This growth was driven by a new product launches, continued expansion into new markets, and leveraging our strong manufacturing capabilities. We also completed the Xellia acquisition which has expanded our injectable portfolio pipeline manufacturing capacity and R&D strength. The Branded business continued to deliver great results benefiting from our strong position in the MENA region. Our focus on supplying high-quality high value medicines including oncology products has driven both margin expansion and revenue growth.

Generics also had an excellent year, with double-digit core revenue growth and a solid profit margin. We have new leadership in this business and I'm extremely excited about the potential here. We're focusing on accelerating R&D, executing our new CMO relationship and expanding our operational technologies to ensure stable and consistent growth in the years ahead.

I am pleased to share we are guiding to another year of profitable growth in 2025, and we look forward to updating all of our stakeholders on our progress throughout the year.

Finally, I would like to thank all Hikma employees, without their dedication, we wouldn't have been able to make our high-quality medicines accessible to those who need them the most. Their commitment is at the core of our purpose, putting better health within which, every day.